Forward-Looking Statements

This website and the materials it contains include "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the anticipated development of prifemilast; the design, timing, initiation, enrollment, and results of planned or ongoing clinical studies; the potential safety, tolerability, efficacy, and therapeutic benefits of prifemilast; cAMPfield's strategy, partnerships, and financing; and the potential market opportunity for our programs.

Forward-looking statements are often identified by words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "will," and similar expressions. These statements are based on cAMPfield's current beliefs and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks related to the early stage of our programs, the uncertain and lengthy nature of drug development and regulatory review, reliance on third parties, competition, and our need for additional funding.

Any forward-looking statement speaks only as of the date on which it is made. Except as required by law, cAMPfield undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investigational product

Prifemilast is an investigational drug candidate that has not been approved, licensed, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any indication. The safety and efficacy of prifemilast have not been established. Nothing on this website constitutes a promotion, offer, or recommendation of any investigational product.